Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 112

1.

β-Blockers, heart disease and COPD: current controversies and uncertainties.

Baker JG, Wilcox RG.

Thorax. 2017 Mar;72(3):271-276. doi: 10.1136/thoraxjnl-2016-208412. Epub 2016 Dec 7.

PMID:
27927840
2.

Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.

Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG.

Heart. 2015 May;101(9):692-8. doi: 10.1136/heartjnl-2014-306686. Epub 2015 Feb 17.

PMID:
25691510
3.

Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study).

Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, Lopes RD, Steg PG, Armstrong PW.

Am J Cardiol. 2014 Sep 15;114(6):811-9. doi: 10.1016/j.amjcard.2014.06.011. Epub 2014 Jul 8.

PMID:
25108302
4.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators..

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.

5.

Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial.

Armstrong PW, Westerhout CM, Van de Werf F, Califf RM, Welsh RC, Wilcox RG, Bakal JA.

Am Heart J. 2011 May;161(5):848-54. doi: 10.1016/j.ahj.2010.12.026. Epub 2011 Apr 7.

PMID:
21570513
6.

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, Erdmann E, Defronzo RA, Laakso M.

Diabetes Obes Metab. 2011 Aug;13(8):759-64. doi: 10.1111/j.1463-1326.2011.01404.x.

PMID:
21457426
7.

Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators..

Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x.

PMID:
21388447
8.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee..

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
9.

Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.

Simes RJ, O'Connell RL, Aylward PE, Varshavsky S, Diaz R, Wilcox RG, Armstrong PW, Granger CB, French JK, Van de Werf F, Marschner IC, Califf R, White HD; HERO-2 Investigators..

Am Heart J. 2010 Jun;159(6):988-97. doi: 10.1016/j.ahj.2009.12.044.

PMID:
20569711
10.

Retrograde catheterisation vs. Doppler echocardiographic evaluation of aortic stenosis--a survey of contemporary UK practice.

Fazal IA, Alfakih K, Wilcox RG, Walsh JT.

Int J Cardiol. 2009 May 1;134(1):138-9. doi: 10.1016/j.ijcard.2007.12.049. Epub 2008 Mar 26.

PMID:
18372062
11.
12.

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.

Erdmann E, Wilcox RG.

Eur Heart J. 2008 Jan;29(1):12-20. doi: 10.1093/eurheartj/ehm529. Review.

PMID:
18167366
13.

Enhanced platelet aggregation and activation under conditions of hypothermia.

Xavier RG, White AE, Fox SC, Wilcox RG, Heptinstall S.

Thromb Haemost. 2007 Dec;98(6):1266-75.

PMID:
18064324
14.

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP.

J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6. Epub 2007 Oct 23.

15.

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators..

Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.

PMID:
17666462
16.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators..

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.

17.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
18.

The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.

Brener SJ, Lincoff AM, Bates ER, Jia G, Armstrong PW, Guetta V, Hochman JS, Savonitto S, Wilcox RG, White HD, Topol EJ; GUSTO V Investigators..

Am Heart J. 2005 Jul;150(1):89-93.

PMID:
16084153
19.

Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.

Nallamothu BK, Bates ER, Hochman JS, Granger CB, Guetta V, Wilcox RG, White HD, Armstrong PW, Savonitto S, Jia G, Lincoff AM, Topol EJ; GUSTO-V Investigators..

Eur Heart J. 2005 Aug;26(15):1506-12. Epub 2005 Mar 30.

PMID:
15800019
20.

Clopidogrel resistance.

Heptinstall S, Glenn JR, May JA, Storey RF, Wilcox RG.

Catheter Cardiovasc Interv. 2004 Nov;63(3):397-8. No abstract available.

PMID:
15505861

Supplemental Content

Loading ...
Support Center